UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 10-Q

     |X| Quarterly Report Pursuant To Section 13 or 15(d) of The Securities
                              Exchange Act Of 1934

                  For the quarterly period ended June 30, 2012

   |_| Transition Report Under Section 13 or 15(d) of The Securities Exchange
                                   Act Of 1934

             For the transition period from __________ to __________

                        Commission File Number: 000-53316

                                TRANSBIOTEC, INC.
                           -------------------------
             (Exact name of registrant as specified in its charter)

           Delaware                                       26-0731818
 --------------------------------          ------------------------------------
 (State or other jurisdiction              (I.R.S. Employer Identification No.)
of incorporation or organization)

                        3030 Old Ranch Parkway, Suite 350
                              Seal Beach, CA 90740
                          ---------------------------
          (Address of principal executive offices, including Zip Code)

                                 (562) 280-0483
                             ----------------------
                (Issuer's telephone number, including area code)

                       -----------------------------------
          (Former name or former address if changed since last report)

Check  whether the issuer (1) filed all reports  required to be filed by section
13 or 15(d) of the  Exchange  Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports),  and (2) has been
subject to such filing requirements for the past 90 days. Yes [x] No [ ]

Indicate by check mark whether the registrant has submitted  electronically  and
posted on its corporate Web site, if any, every  Interactive  Data File required
to be submitted and posted pursuant to Rule 405 of Regulation S-T (ss.232.405 of
this chapter)  during the  preceding 12 months (or for such shorter  period that
the registrant was required to submit and post such files). Yes [ ] No [ ]

Indicate by check mark whether the registrant is a large  accelerated  filer, an
accelerated filer, a non-accelerated  filer, or a small reporting  company.  See
the   definitions   of   "large   accelerated   filer,"   "accelerated   filer,"
"non-accelerated  filer," and "smaller  reporting  company" in Rule 12b-2 of the
Exchange Act.

Large accelerated filer      [ ]         Accelerated filer         [ ]

Non-accelerated filer        [ ]         Smaller reporting company [x]

Indicate by check mark whether the  registrant is a shell company (as defined in
Rule 12b-2 of the Exchange Act). Yes [ ] No [X]

State the number of shares outstanding of each of the issuer's classes of common
equity, as of the latest practicable date:  28,150,427 shares of common stock as
of August 14, 2012.


<PAGE>


                                TransbioTec, Inc.
                          (A Development Stage Company)
                           CONSOLIDATED BALANCE SHEETS
                                               June. 30, 2012
                                                 (unaudited)     Dec. 31, 2011
                                               --------------    -------------
   ASSETS
       Cash                                    $       215       $    108,019
       Due from Triumph Capital                        100                100
       Prepaid expenses                              2,127                192
                                               --------------    -------------
          Total current assets                       2,442            108,311
                                               --------------    -------------
       Fixed assets - net                            1,799              1,132
                                               --------------    -------------
     Total Assets                              $     4,241       $    109,443
                                               ==============    =============
   LIABILITIES & STOCKHOLDERS' EQUITY
     Current liabilities
       Accounts payable                        $   237,952       $    207,660
       Accrued interest payable                    117,763             87,411
       Notes payable - current - related
        parties                                    381,635            191,260
       Notes payable - current                     214,159             86,000
       Note discount                               (28,023)
       Notes payable - 8% Debenture                      -             30,000
       Related party payables                      286,501            288,448
       Other payables                              157,988            158,006
                                               --------------    -------------
         Total current liabilities               1,367,975          1,048,785
                                               --------------    -------------
       Notes payable - related parties             330,865            549,263
                                               --------------    -------------
     Total Liabilities                           1,698,840          1,598,048
                                               --------------    -------------
     Stockholders' Equity
       Common stock, $.00001 par value;
        100,000,000 shares authorized;
        28,150,427 and 25,471,672
        shares issued and outstanding
        at June 30, 2012 and December
        31, 2011 respectively.                         282                254
       Additional paid in capital               11,345,996          9,266,959
        Deficit accumulated during the
         development stage                     (13,000,823)       (10,720,938)
                                               --------------    -------------
        Total Transbiotec
         stockholders' equity                   (1,654,545)        (1,453,725)
        Noncontrolling interest                    (40,054)           (34,880)
                                               --------------    -------------
     Total Stockholders' Equity                 (1,694,599)        (1,488,605)
                                               --------------    -------------
     Total Liabilities and Stockholders'
      Equity                                   $     4,241        $   109,443
                                               ==============    =============

         The accompanying notes are an integral part of the consolidated
                             financial statements.

                                       2
<PAGE>

<TABLE>
<S>                                                <C>            <C>            <C>            <C>              <C>

                                                         TransbioTec, Inc.
                                                   (A Development Stage Company)
                                               CONSOLIDATED STATEMENTS OF OPERATIONS
                                                                                                               Period From
                                                For Three Months Ended         For Six Months Ended           July 19, 2004
                                                       June 30,                      June 30,                (Inception) To
                                                 2012           2011           2012            2011           June 30, 2012
                                             -------------- -------------- --------------  -------------    ------------------

   Revenues                                  $           -  $           -  $           -   $           -    $           -
                                             -------------- -------------- --------------  -------------    ------------------
                                                         -              -              -               -                -
                                             -------------- -------------- --------------  -------------    ------------------
   Operating expenses:
        Amortization & depreciation                      -             71            151             770           75,895
        General and administrative                 145,699         90,871      2,176,847         150,062       11,858,085
                                             -------------- -------------- --------------  -------------    ------------------
                                                   145,699         90,942      2,176,998         150,832       11,933,980
                                             -------------- -------------- --------------  -------------    ------------------
   Gain (loss) from operations                    (145,699)       (90,942)    (2,176,998)       (150,832)     (11,933,980)
                                             -------------- -------------- --------------  -------------    ------------------
   Other income (expense):
        Gain on sale of fixed asset                      -              -          4,790               -            4,790
        Interest expense                           (20,777)       (53,835)       (48,680)        (12,449)      (1,0023,645)
        Interest expense - beneficial
         conversion feature                        (44,035)             -        (64,171)              -         (134,171)
                                             -------------- --------------  -------------    ------------------ -----------
                                                   (64,812)       (53,835)      (108,061)       (112,449)      (1,153,026)
                                             -------------- -------------- --------------  -------------    ------------------
   Income (loss) before provision for
    income taxes                                  (210,511)      (144,777)    (2,285,059)       (263,281)     (13,087,006)
   Provision for income tax                              -              -              -               -                -
                                             -------------- -------------- --------------  -------------    ------------------
   Net income (loss)                              (210,511)      (144,777)    (2,285,059)       (263,281)     (13,087,006)
     Less: Net (income) loss attributable
      to noncontrolling interest                     2,095              -          5,174               -           86,183
                                             -------------- -------------- --------------  -------------    ------------------
   Net income (loss) attributable to
    Transbiotec                              $    (208,416) $    (144,777) $  (2,279,885)  $    (263,281)   $(13,000,823)
                                             ============== ============== ==============  =============    ==================
   Net income (loss) per share
    (Basic and fully diluted)                $       (0.01) $       (0.02) $       (0.08)  $       (0.03)
                                             ============== ============== ==============  =============
   Weighted average number of
    common shares outstanding                   28,007,094      9,309,450     26,952,017       9,309,450
                                             ============== ============== ==============  =============
</TABLE>

               The accompanying notes are an integral part of the
                       consolidated financial statements.


                                       3
<PAGE>


                                         TransbioTec, Inc.
                                   (A Development Stage Company)
                               CONSOLIDATED STATEMENTS OF CASH FLOWS
<TABLE>
<S>                                               <C>           <C>           <C>


                                                                          Period From
                                                                         July 19, 2004
                                                For Six Months Ended     (Inception)
                                                       June 30,               To
                                                 2012          2011      June 30. 2012
                                             -------------  -----------  --------------

   Cash Flows From Operating Activities:

     Net income (loss)                       $(2,285,059)   $ (263,281)   (13,094,148)

     Adjustments to reconcile net loss to
      net cash provided by (used for)
      operating activities:
        Amortization & depreciation                  303           770         76,046

        Compensatory equity issuances          1,888,871             -      8,228,188

        Asset write offs                             850             -         38,363

        Accrued payables                           3,621       131,768      1,917,107
        Gain on sale of fixed asset               (4,790)            -         (4,790)
        Note payable/ beneficial
         conversion expense                       92,194             -        365,758
        Original issue discount -
         interest expense                              -             -         40,000
                                             -------------  -----------  --------------
           Net cash provided by (used
            for) operating activities           (304,010)     (130,743)    (2,340,151)
                                             -------------  -----------  --------------


   Cash Flows From Investing Activities:
        Proceeds received on sale of
         fixed asset                               4,790             -          4,790

        Fixed asset purchases                       (970)            -        (77,845)
                                             -------------  -----------  --------------
        Net cash provided by (used
         for) investing activities                 3,820             -        (73,055)
                                             -------------  -----------  --------------
</TABLE>


         The accompanying notes are an integral part of the consolidated
                             financial statements.

                          (Continued On Following Page)

                                       4
<PAGE>

                                TransbioTec, Inc.
                          (A Development Stage Company)
                      CONSOLIDATED STATEMENTS OF CASH FLOWS


                         (Continued From Previous Page)

<TABLE>
<S>                                               <C>           <C>           <C>


                                                                          Period From
                                                                         July 19, 2004
                                                For Six Months Ended     (Inception)
                                                       June 30,               To
                                                 2012          2011      June 30. 2012
                                             -------------  -----------  --------------

   Cash Flows From Financing Activities:
        Notes & loans payable -
         borrowings                               94,386         2,845        950,647
        Notes & loans payable -
         payments                                      -        (6,500)       (38,726)
        Repurchase of equity                           -       (24,688)      (250,000)
        Equity issuances                          98,000       172,812      1,751,500
                                             -------------  -----------  --------------
           Net cash provided
            by (used for) financing
            activities                           192,386       144,469      2,413,421
                                             -------------  -----------  --------------

   Net Increase (Decrease) In Cash              (107,804)       13,726            215


   Cash At The Beginning Of The Period           108,019        30,695              -
                                             -------------  -----------  --------------

   Cash At The End Of The Period             $       215    $   44,421   $        215
                                             =============  ===========  ==============


   Schedule Of Non-Cash Investing And Financing Activities
$
   Compensatory equity issuances             $ 1,888,871    $        -   $  8,228,188

   Debt converted to capital                 $    43,000    $  433,669   $  1,530,875

   Supplemental Disclosure

   Cash paid for interest                    $     4,500    $      563   $     11,735

   Cash paid for income taxes                $         -    $        -   $          -
</TABLE>

               The accompanying notes are an integral part of the
                       consolidated financial statements.

                                       5
<PAGE>

                                TransBioTec, Inc.
                          (A Development Stage Company)
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS



NOTE 1. ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Imagine Media,  LTD. was  incorporated  in August 2007 in the State of Delaware.
TransBioTec,  Inc. was formed in the state of California in July 2004. Effective
September 19, 2011 Imagine Media,  LTD. was acquired by  TransBioTec,  Inc. in a
transaction classified as a reverse acquisition.  In January 2012 Imagine Media,
LTD.  changed its name to TransBioTec,  Inc.,  resulting in a parent company and
subsidiary of the same name. The financial  statements represent the activity of
TransBioTec,  Inc. from July 19, 2004 forward, and the consolidated  activity of
Imagine  Media,  LTD. and  TransBioTec,  Inc.  from  September 19, 2011 forward.
Imagine  Media,  LTD.  and  TransBioTec,   Inc.  are  hereinafter   referred  to
collectively as the "Company". The Company has developed and plans to market and
sell a non-invasive alcohol sensing system which includes an ignition interlock.
The Company is currently  considered to be in the development stage, and has not
generated revenues from its activities.

Principles of Consolidation
---------------------------

The accompanying  consolidated  financial statements include the accounts of the
Company  and its  majority  owned  subsidiary.  All  intercompany  accounts  and
transactions have been eliminated in consolidation.

Use of Estimates
----------------

The preparation of financial  statements in conformity  with generally  accepted
accounting principles requires management to make estimates and assumptions that
affect  reported  amounts of assets and liabilities and disclosure of contingent
assets and liabilities at the date of the financial  statements and the reported
amounts of revenues and expenses  during the reporting  period.  Actual  results
could differ from those estimates.

Cash and cash equivalents
-------------------------

The Company considers all highly liquid investments with an original maturity of
three months or less as cash equivalents.

Accounts receivable
-------------------

The Company reviews  accounts  receivable  periodically for  collectability  and
establishes an allowance for doubtful accounts and records bad debt expense when
deemed  necessary.  At June 30,  2012,  and 2011 the  Company  had no balance in
accounts receivable or the allowance for doubtful accounts.

                                       6
<PAGE>

                                TransBioTec, Inc.
                          (A Development Stage Company)
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


NOTE 1. ORGANIZATION,  OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
(cont'd)


Property and equipment
----------------------

Property and equipment are recorded at cost and depreciated  under straight line
methods over each item's estimated useful life.

Revenue recognition
-------------------

Revenue is recognized on an accrual basis as earned under  contract  terms.  The
Company has had no revenues to date

Advertising costs
-----------------

Advertising  costs are  expensed as incurred.  The Company  recorded no material
advertising costs during the six months ended June 30, 2012 or 2011.

Income tax
----------

The  Company  accounts  for  income  taxes  pursuant  to ASC 740.  Under ASC 740
deferred taxes are provided on a liability  method  whereby  deferred tax assets
are  recognized for deductible  temporary  differences  and operating loss carry
forwards and deferred  tax  liabilities  are  recognized  for taxable  temporary
differences.  Temporary  differences  are the  differences  between the reported
amounts of assets and liabilities  and their tax bases.  Deferred tax assets are
reduced by a valuation allowance when, in the opinion of management,  it is more
likely than not that some  portion or all of the deferred tax assets will not be
realized.  Deferred tax assets and  liabilities  are adjusted for the effects of
changes in tax laws and rates on the date of enactment.

Net income (loss) per share
---------------------------

The net income (loss) per share is computed by dividing the net income (loss) by
the weighted  average number of shares of common  outstanding.  Warrants,  stock
options,  and  common  stock  issuable  upon  the  conversion  of the  Company's
preferred  stock (if any),  are not  included in the  computation  if the effect
would be  anti-dilutive  and would  increase the  earnings or decrease  loss per
share.

Financial Instruments
---------------------

The carrying value of the Company's  financial  instruments,  as reported in the
accompanying balance sheets, approximates fair value.

                                       7
<PAGE>

                                TransBioTec, Inc.
                          (A Development Stage Company)
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


NOTE 1. ORGANIZATION,  OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
(cont'd)

Long-Lived Assets
-----------------

In accordance with ASC 350, the Company  regularly reviews the carrying value of
intangible  and  other   long-lived   assets  for  the  existence  of  facts  or
circumstances,  both internally and externally,  that may suggest impairment. If
impairment  testing  indicates a lack of  recoverability,  an impairment loss is
recognized by the Company if the carrying  amount of a long-lived  asset exceeds
its fair value.

Products and services, geographic areas and major customers
-----------------------------------------------------------

The Company is currently in the developmental stage and has no revenue.

Stock based compensation
------------------------

The Company accounts for employee and  non-employee  stock awards under ASC 718,
whereby equity  instruments  issued to employees for services are recorded based
on the fair value of the instrument issued and those issued to non-employees are
recorded based on the fair value of the consideration received or the fair value
of the equity instrument, whichever is more reliably measurable.

Minority Interest (Noncontrolling Interest)
-------------------------------------------

A  subsidiary  of the  Company  has  minority  members,  representing  ownership
interests of 2.46% at June 30, 2012. The Company accounts for these minority, or
noncontolling  interests  pursuant to ASC 810-10-65 whereby gains or losses in a
subsidiary with a  noncontrolling  interest are allocated to the  noncontrolling
interest based on the ownership percentage of the noncontrolling  interest, even
if that allocation results in a deficit noncontrolling interest balance.

NOTE 2. RELATED PARTY TRANSACTIONS

During the six months  ended June 30,  2012 and June 30,  2011,  the Company had
payables  due to officers  for  accrued  compensation  of $33,445  and  $157,827
respectively.

In 2010 an officer  converted  $325,000 in  compensation  owed him into  516,750
common   shares.   During  the  year  ended  December  31,  2011  related  party
shareholders  converted  $829,164 in note principal and interest and $135,000 in
compensation into 2,408,977 common shares.

                                       8
<PAGE>

                                TransBioTec, Inc.
                          (A Development Stage Company)
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 3. FIXED ASSETS

Fixed asset values recorded at cost are as follows:

                                               December 31,
                                       ------------------------   (Unaudited)
                                           2010          2011    June 30, 2012
                                       ----------     ---------  -------------

Automobile                             $   33,383     $  33,383      $      -
Office and Lab Equipment                   31,896        31,896        31,616
Furniture and fixtures                     11,596        11,596        11,556
                                       ----------     ---------      --------
                                           76,875        76,875        43,172
Less accumulated depreciation             (74,832)      (75,743)      (41,373)
                                       ----------     ---------      --------
Total                                  $    2,043     $   1,132      $  1,799
                                       ==========     =========      ========


Depreciation  expense  for the six months  ended June 30, 2012 and June 30, 2011
was $152 and $770 respectively.

NOTE 4. NOTES PAYABLE



                                 December 31,   December 31,      (Unaudited)
                                 ------------   ------------      -----------
                                     2010            2011        June 30, 2012
                                     ----            ----        -------------


Note payable to related party,
unsecured, due 8/3/2012,            $1,950          $1,950         $1,950
interest rate 0%

                                       9
<PAGE>

Note payable to related party,    $184,156                -             -
unsecured, due 9/17/2008,
convertible at holder's option
at $1 per share,
interest rate 10% plus agreed
upon amounts

Note payable to related party,    $150,000                -             -
unsecured, due 12/15/2013,
monthly interest due,
convertible at holder's option
at $2.50 per share,
interest rate 22.1%

Note payable to related party,    $240,000                -             -
unsecured, due 05/28/2009,
convertible at holder's option
at $2.50 per share,
original   issue   discount  of
20%, with interest at
$444 per day after due date

Note payable to related party,    $151,929                -             -
unsecured, due 07/27/2012,
convertible at holder's option
at $2.50 per share,
interest rate 8%

Notes payable to related            $5,000                -             -
parties, unsecured, due
01/29/2011, convertible
at holder's option at $2.50
per share, interest rate 9%

Notes payable to  related          $15,810          $11,810       $11,810
parties, unsecured, due
12/31/2012, interest rate 0%

Note payable to related party,           -          $16,000       $16,000
unsecured, due 09/15/2012,
convertible at holder's option
at $2.50 per  TransBioTec
share.

Note payable to related party,          -           $10,000        $10,000
lien against company assets,
unsecured, due 2/8/12,
quarterly interest
due, convertible at holder's
option at $0.3235688 per IMLE
share, interest rate 30%


                                       10
<PAGE>

Note payable to related party,
lien against company assets,            -           $25,000        $25,000
unsecured, due 2/8/12,
quarterly interest due,
convertible at holder's option
at $0.3235688 per IMLE share,
interest rate 30%

Note payable to related party,          -           $25,000        $25,000
lien against company assets,
unsecured, due 2/17/12,
quarterly interest due,
convertible at holder's option
at $0.3235688 per IMLE share,
interest rate 30%

Note payable to related party,
lien against company assets,            -           $10,000        $10,000
unsecured, due 2/18/12,
quarterly interest due,
convertible at holder's option
at $0.3235688 per IMLE share,
interest rate 30%

Note payable to related party,
unsecured, due 2/18/13, annual          -                 -           $750
interest due, convertible at
holder's option at $0.3235688
per IMLE share, interest rate
18%

Note payable to related party,          -                 -         $6,875
unsecured, due 2/18/13, annual
interest due, convertible at
holder's option at $0.3235688
per IMLE share, interest rate
18%

Note payable to related party,          -                 -         $2,500
unsecured, due 2/15/13, annual
interest due, convertible at
holder's option at $0.3235688
per IMLE share, interest rate
12%


                                       11
<PAGE>

Note payable to related party,          -                 -         $3,750
unsecured, due 2/20/13,
annual interest due, convertible
at holder's option at $0.3235688
per IMLE share, interest rate 12%

Note payable to related party,          -                 -         $2,625
unsecured, due 2/21/13, annual
interest due, convertible at
holder's option at $0.3235688
per IMLE share, interest rate
12%

Note payable to related party,          -                 -         $5,433
unsecured, due 3/20/13, annual
interest due, convertible at
holder's option at $0.3235688
per IMLE share, interest rate
12%

Note payable to related party,          -                 -         $3,203
unsecured, due 3/22/13, annual
interest due, convertible at
holder's option at $0.3235688
per IMLE share, interest rate
12%

Note payable to related party,          -                 -        $37,500
lien against company assets,
unsecured, due 1/05/13, annual
interest due, convertible at
holder's option at 51% of
market as defined, interest
rate 8%, conversion limited to
total beneficial ownership of
4.99%

Note payable to related party,          -                 -        $37,500
lien against company assets,
unsecured, due 2/25/13, annual
interest due, convertible at
holder's option at 51% of
market as defined, interest
rate 8%, conversion limited to
total beneficial ownership of
4.99%

Note payable to related party,          -                 -       $726,763
unsecured, lien against
company assets, $731,763, 5-years
at 0% simple interest, due
7/1/2016, payment
amounts vary each month.

                                       12
<PAGE>

                                $ 748,845         $ 826,523       $926,659
Less Note discounts                     -                 -        (28,023)
Less current portion             (594,966)         (277,260)      (567,771)
                                ---------         ---------       --------

Long-term portion               $153,879          $ 549,263       $330,865
                                ========          =========       ========

Required principal payments from December 31, 2011 forward are as follows:

                  2012               $ 282,260
                  2013               $ 285,511
                  2014               $ 196,881
                  2015               $ 123,709
                  2016               $  38,298
                                     ---------
                                     $ 926,659

Interest  expense under notes payable for the six months ended June 30, 2012 and
June 30, 2011 was $40,788 and $107,575, respectively.

During  the six  months  ended  June 30,  2012 and  June  30,  2011 the  Company
recognized a beneficial conversion feature expense on borrowing from convertible
notes of $64,171 and none, respectively.

Convertible debenture payable
to unrelated party, unsecured,
due 04/1/2009, convertible at
holder's option at $.25 per
share, interest rate 8% Default
interest rate 12%                $ 30,000         $  30,000       $      -


                                       13
<PAGE>

                                TransBioTec, Inc.
                          (A Development Stage Company)
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


NOTE 5. INCOME TAXES

Deferred  income taxes arise from the temporary  differences  between  financial
statement  and  income  tax  recognition  of net  operating  losses.  These loss
carryovers  are limited  under the Internal  Revenue  Code should a  significant
change in ownership occur.


NOTE 6.  STOCK OPTIONS

The Company accounts for employee and non-employee  stock options under ASC 718,
whereby option costs are recorded  based on the fair value of the  consideration
received or the fair value of the equity instruments  issued,  whichever is more
reliably  measurable.  Unless otherwise  provided for, the Company covers option
exercises by issuing new shares.

The Company's stock option activity is described below.

Non-employee stock options
--------------------------

At the  beginning  of 2010 the Company  had 10,000  non-employee  stock  options
outstanding  in the  Company's  subsidiary  TransBiotec,  Inc.  During  2010 the
Company granted 22,500 options for services, allowing the holder to purchase one
share of common stock per option, with 22,500 options exercisable immediately at
prices from $0.10 - $0.15 per share with the option terms  expiring from January
2012 through January 2015. During 2011 no options were exercised, and no options
expired,  leaving a 2010 year end  outstanding  balance  of 32,500  non-employee
stock  options.  The  fair  value  of the  22,500  options  granted  in 2010 was
estimated on the date of grant using the Black-Scholes option pricing model with
the following  assumptions:  risk free interest rate of 1.08% - 2.67%,  dividend
yield of 0%,  expected  lives of 2 - 5 years,  volatility  of 100%.  The Company
incurred and recorded  compensation  expense  under these stock option grants of
$53,262 in 2010.

During the six months ended June 30, 2012, 10,000 options were exercised, and no
options  expired,  leaving  a  June  30,  2012  outstanding  balance  of  22,500
non-employee  stock options,  exercisable at prices from $0.10 - $0.15 per share
with the option terms expiring from July 2012 through January 2015.


                                       14
<PAGE>

                                TransBioTec, Inc.
                          (A Development Stage Company)
                  NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 6.  STOCK OPTIONS (cont'd)

Employee stock options
----------------------

The Company had no outstanding employee stock options in 2010 or 2011, or during
the six months ended June 30, 2012.

NOTE 7. GOING CONCERN

The Company has  suffered  recurring  losses from  operations  and has a working
capital  deficit  and  stockholders'  deficit,  and in all  likelihood  will  be
required to make significant  future  expenditures in connection with continuing
marketing efforts along with general administrative  expenses.  These conditions
raise  substantial  doubt  about the  Company's  ability to  continue as a going
concern.

The  Company  may  raise  additional  capital  through  the  sale of its  equity
securities,  through an offering of debt securities,  or through borrowings from
financial  institutions  or others.  By doing so, the Company  hopes to generate
revenues from sales of its alcohol sensing and ignition lock systems. Management
believes that actions presently being taken to obtain additional funding provide
the opportunity for the Company to continue as a going concern.


                                       15
<PAGE>

Item 2. Management's  Discussion and Analysis of Financial  Condition and Plan
        of Operation

     The  Company  was formed in August  2007 to publish  and  distribute  Image
Magazine,  a monthly  guide and  entertainment  source for the Denver,  Colorado
area. The Company  generated only limited revenue and essentially  abandoned its
business plan in January 2009.

     In January 2012 the Company completed its acquisition of TransBiotec,  Inc.
("TBT") a California corporation.

     As a result of the  acquisition,  TBT's  business is that of the Company's,
and,  unless  otherwise  indicated,  any  references to the Company  include the
business and operations of TBT.

     The Company, now headquartered in Seal Beach, California, has developed and
patented a high technology,  state-of-the-art  transdermal  sensor system,  that
detects blood alcohol  levels  through a person's  skin.  Ethanol is produced as
alcohol is ingested  and  metabolized  in the body.  The system  senses  ethanol
excreted through  perspiration.  A person places their finger on the sensor, and
within 5-8 seconds,  the sensor will detect the ethanol level. A signal can then
be sent to output  devices  that control the ignition in a vehicle to prevent it
from starting.  The system can also communicate with other devices such as a GPS
unit, or cell phone.

     The Company's system is unobtrusive, accurate, reliable, durable, low cost,
easier to use and faster than the current breathalyzer applications. The Company
has  completed  its beta testing of the sensor and is currently  developing  its
manufacturing capability.

     Initially,  the  Company  intends to offer its sensor  only for  commercial
vehicle  applications.  Later,  the  Company  plans to market  its sensor to the
public for use in automobiles, SUV's, RV's, boats and other vehicles.

     The following discussion:

          o    summarizes the Company's plan of operation; and

          o    analyzes the Company's financial condition and the results of its
               operations for the six months ended June 30, 2012.

     This  discussion  and  analysis  should  be read in  conjunction  with  the
Company's financial statements included as an exhibit to this report.

Plan of Operation and Capital Requirements
------------------------------------------

     The Company's plan of operations is as follows:

                                       16
<PAGE>

                                                       Projected      Estimated
   Activity                                          Completion Date     Cost
   --------                                          ---------------     ----

   Develop relationship with initial customers
   willing to work with Company in refining SOBR.
   Will discount price for units sold to customers
   who partner with Company in this phase.
   Identify add-on features that may appeal to
   customers. Complete design of printed circuit
   boards and injection molding tools. Sales target
   of 500 units.                                      December 2012    $160,000

   Outsource manufacturing, packaging and shipping.
   Complete joint venture agreement with GPS partner.
   Develop add-on features such as cameras, GPS and
   radio interfaces, and a fingerprint reader which
   would allow the SOBR to determine the driver's
   identity and blood alcohol content at the same
   time.  Improve production capability to 1,000
   units per month.                                   February 2013    $370,000

   Improve manufacturing capability to 10,000
   units per month.                                       June 2013    $370,000

     The Company will maintain its research and development  efforts with a goal
of continuously improving the SOBR.

     The Company's sources and (uses) of funds for the six months ended June 30,
2012 and 2011 are shown below:

                                             For the six months ended
                                             ------------------------
                                                    June 30,
                                                    --------
                                             2012                2011
                                             ----                ----

Net cash provided by (used for)
  operations                              $(304,010)          $(130,743)

Sale of equipment                         $   4,790           $       -

Purchase of equipment                     $    (970)          $       -

Loans, net of loan repayments             $  94,386           $  (3,655)

Repurchase of common stock                $      --           $ (24,688)

Sale of stock                             $  98,000           $ 172,812

Cash on hand at beginning of the
 period                                   $ 107,804           $       -


     The Company does not have any off-balance  sheet  arrangements that have or
are  reasonable  likely  to have a  current  or  future  material  effect on its
financial  condition,  changes in financial  condition,  results of  operations,
liquidity or capital resources.

                                       17
<PAGE>

     Other than as  disclosed  above,  the Company  does not know of any trends,
demands,  commitments,  events or  uncertainties  that will  result  in, or that
reasonably likely to result in, the Company's liquidity increasing or decreasing
in any material way.

     Other than as disclosed above, the Company does not know of any significant
changes in its expected sources and uses of cash.

Results of Operations
---------------------

     The Company was formed in August 2007 and  generated  only limited  revenue
before it effectively ceased operations in January 2009.

     Material changes in the Company's Statement of Operations for the three and
six months ended June 30, 2012 as compared to the same periods in the prior year
are discussed below:

                                      Increase (I)
Item                                or Decrease (D)  Reason
----                                ---------------  ------

General and Administrative Expenses        I         Value of  shares  issued to
                                                     financial consultant.

Item 4.  Controls and Procedures.

     (a) The Company  maintains a system of controls and procedures  designed to
ensure that  information  required to be disclosed in reports filed or submitted
under the Securities Exchange Act of 1934, as amended ("1934 Act"), is recorded,
processed,  summarized and reported,  within time periods specified in the SEC's
rules and forms and to ensure that  information  required to be disclosed by the
Company  in the  reports  that it files  or  submits  under  the  1934  Act,  is
accumulated  and  communicated  to  the  Company's  management,   including  its
Principal  Executive  and  Financial  Officer,  as  appropriate  to allow timely
decisions  regarding  required  disclosure.  As of June 30, 2012,  the Company's
Principal  Executive and Financial  Officer  evaluated the  effectiveness of the
design and operation of the Company's disclosure controls and procedures.  Based
on that evaluation, the Principal Executive and Financial Officer concluded that
the Company's disclosure controls and procedures were effective.

     (b) Changes in Internal  Controls.  There were no changes in the  Company's
internal  control over  financial  reporting  during the quarter  ended June 30,
2012, that materially  affected,  or are reasonably likely to materially affect,
its internal control over financial reporting.


                                       18
<PAGE>


                                     PART II

Item 6.  Exhibits

Exhibits

  31.1    Certification  pursuant  to  Section  302 of the Sarbanes-Oxley Act of
          2002.

  31.2    Certification  pursuant to Section 302 of the Sarbanes-Oxley Act of
          2002.

  32      Certification  pursuant to Section 906 of the Sarbanes-Oxley Act.


                                       19
<PAGE>

                                   SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.




                                      TRANSBIOTEC, INC.


August 14, 2012                        By: /s/ Scott Painter
                                           ----------------------------------
                                           Scott Painter, Principal Executive,
                                           Financial and Accounting Officer

                                       20
<PAGE>